CompletedNot Applicable

Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)

United States10 participantsStarted 2022-09-22

Plain-language summary

Prospective, single center, open label, non-randomized, post-market study of the Tablo Hemodialysis System and VitalStream Monitor in participants with End-Stage KidneyDisease undergoing In-Center Hemodialysis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant is at least 18 years of age and has provided informed consent and has signed a Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant authorization statement. * Participant weighs ≥ 34kg. * Participant has end stage kidney disease (ESKD) adequately treated by maintenance dialysis. Exclusion Criteria: * Participant has lack of perfusion of the digitalarteries and arterioles in the lower arm and hand. * The Non-Invasive Blood Pressure (NIPB) monitorcuffs (finger and/or brachial) are unable to becorrectly sized to the participant.

What they're measuring

Non-invasive Blood Pressure Monitor (NIPB) Measurements

Timeframe: 7 days from start of participation

Trial details

NCT IDNCT05540457

SponsorThe Rogosin Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-02-09

View on ClinicalTrials.gov More End Stage Renal Disease trials